European Urology
Challenges of Using Circulating Tumour DNA: Insights from Advanced Prostate Cancer
ReviewBiomarkers
Abstract
Precision oncology relies on integrating tumour fraction, variant allele frequency, clonal haematopoiesis of indeterminate potential assessment, pathogenicity, and clinical context into next-generation sequencing interpretation, enabling biologically informed and clinically meaningful treatment decisions while reducing the risk of overinterpreting nontumour or nonactionable genomic alterations.
The paper
Royal Marsden NHS Foundation Trust
European Urology, 15 Sep 2026



